What is Praluent’s list price?
Praluent (alirocumab) is sold at about $1,350 per month, or roughly $16,200 annually in the United States. The drug is delivered by injection every two weeks, and the manufacturer lists the cost for 80 mg vials used at that frequency.
How do insurance plans treat it?
Most commercial insurers consider Praluent a specialty drug and require prior authorization. After approval, the insurer usually pays the majority of the claim, but patients often face a co‑pay or co‑insurance ranging from $300 to $600 per injection. Medicare Part D plans vary; some add a 20 % co‑insurance for high‑cost drugs, while others require a $2,000 deductible before covering.
What is the patient’s out‑of‑pocket bill?
In a typical scenario, a patient with a standard insurance plan could pay between $600 and $1,200 per month after the deductible, depending on the insurer’s formulary tier and the patient’s cost‑sharing structure. For uninsured patients, the full $1,350 per month must be paid.
Are there assistance programs?
Pfizer offers a patient assistance program for eligible patients who cannot afford Praluent. The program provides the drug at no cost, but patients must meet income and insurance criteria, and they must remain ineligible for insurance coverage for the drug. The application is processed through Pfizer’s website.
How does Praluent compare to other cholesterol drugs?
Statins—such as atorvastatin or simvastatin—are usually $0–$10 per month under generic coverage, making them orders of magnitude cheaper. Other PCSK9 inhibitors (e.g., Repatha) share a similar price point (~$1,200–$1,400 per month). Thus, Praluent is the most expensive option among the few non‑statin LDL‑lowering therapies.
Is it cost‑effective?
Cost‑effectiveness studies have shown that Praluent can be cost‑effective in patients with very high LDL levels who are intolerant to statins, especially when the drug reduces major cardiovascular events. However, many models indicate that its incremental cost‑effectiveness ratio (ICER) exceeds the $50,000–$100,000 per quality‑adjusted life‑year threshold used by many payers, making coverage decisions case‑by‑case.
What do clinicians say about the price?
Some clinicians express concern that the high cost limits access, while others argue that for select patients the benefit-to-cost ratio justifies the expense. The American College of Cardiology has highlighted the need for better pricing transparency.
What should patients do if they’re struggling with the cost?
Patients should first confirm whether their insurance covers Praluent and if a prior authorization is needed. They should also ask their prescriber about the patient assistance program and check for generic alternatives or other statin options.
What are the risks of the high price?
High drug costs can lead to medication non‑adherence, increasing the risk of cardiovascular events. They also strain healthcare budgets, potentially resulting in higher premiums or reduced coverage for other services.
Future pricing trends?
Pricing may shift if competitive biosimilars enter the market or if payer contracts renegotiate. Currently, no biosimilar for Praluent has been approved in the U.S., and the drug’s patents remain in force through the early 2020s, which keeps the price stable.
---
Sources
1. Pfizer, “Praluent (alirocumab) – Drug Information,” https://www.pfizer.com/drugs/alu.
2. Centers for Medicare & Medicaid Services, “Medicare Part D Prescriber and Pharmacy Benefit Management,” https://www.cms.gov/Medicare/PrescriptionDrugBenefitsProgram/PartDPrescriber.
3. American College of Cardiology, “PCSK9 Inhibitors and Cost-Effectiveness,” https://www.acc.org.
4. Medscape, “Praluent (alirocumab) – Cost and Insurance Coverage,” https://www.medscape.com.
5. JAMA Cardiology, “Cost-Effectiveness of PCSK9 Inhibitors,” https://jamanetwork.com.